Посилання

​

1. Інструкція для медичного застосування лікарського засобу Ксеомін. Наказ МОЗ України №973 від 15.09.2016. РП №UA/15447/01/01, № UA/15447/01/02 

2. Jurgen Frevert. Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products//Drugs R D.2015.№15. P.1–9 

3. Grein S et al. Stability of botulinum neurotoxin type A, devoid of complexing proteins//The Botulinum J. 2011. Vol 2, No 1, 49-58. 

4. Grein S et al. Xeomin is stable without refrigeration: Complexing proteins are not required for stability of botulinum neurotoxin type A preparations// Toxicon. Volume 51, Supplement, 1 June 2008, P. 13 

5. Philipp Albrecht et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy// Neurology. 2019;92:1-7.

6. Dirk Dressler et al. Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity// Journal of Neural Transmission. 2018;125(10):1481-1486